PD-L1 and alternative immune checkpoints (AICs) in non-small cell lung cancer (NSCLC): Insights into the tumor immune microenvironment (TIME) and immunotherapy (IO) outcomes

被引：0
|
作者：
D'Aiello, Angelica
Nazari, Shayan
Jeon, Hyein
Elliott, Andrew
Vanderwalde, Ari M.
Borghaei, Hossein
Liu, Stephen V.
Zang, Xingxing
Halmos, Balazs
Cheng, Haiying
机构：
[1] Montefiore Einstein Comprehens Canc Ctr, Bronx, NY USA
[2] Caris Life Sci, Phoenix, AZ USA
[3] Fox Chase Canc Ctr, Philadelphia, PA USA
[4] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[5] Albert Einstein Coll Med, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    He, Jiabei
    Hu, Ying
    Hu, Mingming
    Li, Baolan
    SCIENTIFIC REPORTS, 2015, 5
  • [2] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    Jiabei He
    Ying Hu
    Mingming Hu
    Baolan Li
    Scientific Reports, 5
  • [3] Association of Expression of PD-L1 with the Tumor Immune Microenvironment in Small Cell Lung Cancer
    Yu, Hui
    Badzio, Andrzej
    Boyle, Theresa A.
    Chan, Dan
    Rivard, Christopher J.
    Lu, Xian
    Kowalewski, Ashley A.
    Ellison, Kim
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S222 - S223
  • [4] Associations of the immune microenvironment with PD-L1 copy number alterations and PD-L1 expression in resected non-small cell lung cancer
    Yoshimura, Katsuhiro
    Inoue, Yusuke
    Kahyo, Tomoaki
    Kawase, Akikazu
    Tanahashi, Masayuki
    Ogawa, Hiroshi
    Inui, Naoki
    Funai, Kazuhito
    Shinmura, Kazuya
    Niwa, Hiroshi
    Suda, Takafumi
    Sugimura, Haruhiko
    CANCER RESEARCH, 2017, 77
  • [5] Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
    Jin, Runsen
    Liu, Chengming
    Zheng, Sufei
    Wang, Xinfeng
    Feng, Xiaoli
    Li, Hecheng
    Sun, Nan
    He, Jie
    CANCER BIOLOGY & MEDICINE, 2020, 17 (03) : 768 - 781
  • [6] Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
    Runsen Jin
    Chengming Liu
    Sufei Zheng
    Xinfeng Wang
    Xiaoli Feng
    Hecheng Li
    Nan Sun
    Jie He
    Cancer Biology & Medicine, 2020, 17 (03) : 768 - 781
  • [7] Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
    Runsen Jin
    Chengming Liu
    Sufei Zheng
    Xinfeng Wang
    Xiaoli Feng
    Hecheng Li
    Nan Sun
    Jie He
    Cancer Biology & Medicine , 2020, (03) : 768 - 781
  • [8] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [9] Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
    Papavassiliou, Kostas A. A.
    Marinos, Georgios
    Papavassiliou, Athanasios G. G.
    CELLS, 2023, 12 (06)
  • [10] Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
    Wang, Yuchang
    Chen, Rui
    Wa, Yue
    Ding, Shikuan
    Yang, Yijian
    Liao, Junbo
    Tong, Lei
    Xiao, Gelei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345